Post by Hot Christian Stocks on Jun 13, 2012 12:00:01 GMT -5
ENTB - Entest BioMedical Inc.
Entest BioMedical Inc. develops immuno-therapeutic treatments that
address illnesses and maladies in both veterinary and human medicine.
Of specific interest to us are immunological vaccines for oncology
(cancer vaccines) and veterinary clinic acquisitions.
The basis for the majority of our approaches is underpinned
by leveraging the body's own reparative / immunological
mechanisms - as opposed to using toxic chemicals.
Contact Information
David R. Koos,
Chariman and CEO
Entest BioMedical, Inc.
4700 Spring Street, Suite 304
La Mesa, CA 91942
US
Telephone: 1-619-644-3344
Fax: 1-619-330-2328
Email: info@EntestBio.com
www.entb.net/
www.otcmarkets.com/stock/ENTB/quote
Board of Directors
David R. Koos, PhD, DBA Chairman
David Koos is the Founder, Chairman & CEO of Entest BioMedical Inc. Dr. Koos has over 26 years of investment banking and venture capital experience with a primary focus on fully reporting medical and biotechnology ventures. He holds a Ph.D. degree in Sociology and a Doctor of Business Administration in Finance. Additionally, he has authored / co-authored several peer reviewed journal articles primarily on biotechnology related subjects.
Management Team
David R. Koos, PhD, DBA Chairman
David Koos is the Founder, Chairman & CEO of Entest BioMedical Inc. Dr. Koos has over 26 years of investment banking and venture capital experience with a primary focus on fully reporting medical and biotechnology ventures. He holds a Ph.D. degree in Sociology and a Doctor of Business Administration in Finance. Additionally, he has authored / co-authored several peer reviewed journal articles primarily on biotechnology related subjects.
Feng Lin, MD, PhD - Director of Research
Dr. Feng Linhas a strong background in cell biology, cancer biology and therapy. He also has extensive experience with tissue imaging, and stem cell differentiation. Previously, Dr. Lin was a Senior Research Scientist, Research & Development with Inovio BC, San Diego and Postdoctoral Fellow in the Burnham Institute for Medical Research, La Jolla. He received his M.D. from Central South University Xiangya School of Medicine, Changsha, China, along with a M.S. Biochemistry & Molecular Biology and a Ph.D. Hematology & Physiology from the same institution. Dr. Lin's research work has been widely published in international scientific journals.
ImenVax (TM)
Immuno-Therapeutic Cancer Treatment for Canines
Products & Technologies
Currently, Entest is focused in one area that shows promise for development of an underserved market niche with potentially high demand.
Entest has developed ImenVax™, a novel immuno-therapeutic cancer vaccine which is used in conjunction with an encapsulation devise that enables the patient's body to fight and kill cancer cells.
Immuno-Therapeutic Cancer Vaccine for Canines (Dog Cancer Vaccine)
The first area of focus involves the development of an immuno-therapeutic cancer vaccine for canines. One in every four dogs will develop some sort of cancer during its lifetime. The Company's goal in this area is to create a treatment that will jumpstart the dog's own immune system to fight cancer, and we have a device that is in development that we believe will be a "game-changer" for canine oncology. With the rollout of our "canines first" approach, Entest feels it can penetrate the veterinary market in the very near term (one to three years) and eventually take this immuno-therapeutic cancer vaccine into human trials once enough paid animal cases support our vaccine's efficacy.
Entest BioMedical Inc. develops immuno-therapeutic treatments that
address illnesses and maladies in both veterinary and human medicine.
Of specific interest to us are immunological vaccines for oncology
(cancer vaccines) and veterinary clinic acquisitions.
The basis for the majority of our approaches is underpinned
by leveraging the body's own reparative / immunological
mechanisms - as opposed to using toxic chemicals.
Contact Information
David R. Koos,
Chariman and CEO
Entest BioMedical, Inc.
4700 Spring Street, Suite 304
La Mesa, CA 91942
US
Telephone: 1-619-644-3344
Fax: 1-619-330-2328
Email: info@EntestBio.com
www.entb.net/
www.otcmarkets.com/stock/ENTB/quote
Board of Directors
David R. Koos, PhD, DBA Chairman
David Koos is the Founder, Chairman & CEO of Entest BioMedical Inc. Dr. Koos has over 26 years of investment banking and venture capital experience with a primary focus on fully reporting medical and biotechnology ventures. He holds a Ph.D. degree in Sociology and a Doctor of Business Administration in Finance. Additionally, he has authored / co-authored several peer reviewed journal articles primarily on biotechnology related subjects.
Management Team
David R. Koos, PhD, DBA Chairman
David Koos is the Founder, Chairman & CEO of Entest BioMedical Inc. Dr. Koos has over 26 years of investment banking and venture capital experience with a primary focus on fully reporting medical and biotechnology ventures. He holds a Ph.D. degree in Sociology and a Doctor of Business Administration in Finance. Additionally, he has authored / co-authored several peer reviewed journal articles primarily on biotechnology related subjects.
Feng Lin, MD, PhD - Director of Research
Dr. Feng Linhas a strong background in cell biology, cancer biology and therapy. He also has extensive experience with tissue imaging, and stem cell differentiation. Previously, Dr. Lin was a Senior Research Scientist, Research & Development with Inovio BC, San Diego and Postdoctoral Fellow in the Burnham Institute for Medical Research, La Jolla. He received his M.D. from Central South University Xiangya School of Medicine, Changsha, China, along with a M.S. Biochemistry & Molecular Biology and a Ph.D. Hematology & Physiology from the same institution. Dr. Lin's research work has been widely published in international scientific journals.
ImenVax (TM)
Immuno-Therapeutic Cancer Treatment for Canines
Products & Technologies
Currently, Entest is focused in one area that shows promise for development of an underserved market niche with potentially high demand.
Entest has developed ImenVax™, a novel immuno-therapeutic cancer vaccine which is used in conjunction with an encapsulation devise that enables the patient's body to fight and kill cancer cells.
Immuno-Therapeutic Cancer Vaccine for Canines (Dog Cancer Vaccine)
The first area of focus involves the development of an immuno-therapeutic cancer vaccine for canines. One in every four dogs will develop some sort of cancer during its lifetime. The Company's goal in this area is to create a treatment that will jumpstart the dog's own immune system to fight cancer, and we have a device that is in development that we believe will be a "game-changer" for canine oncology. With the rollout of our "canines first" approach, Entest feels it can penetrate the veterinary market in the very near term (one to three years) and eventually take this immuno-therapeutic cancer vaccine into human trials once enough paid animal cases support our vaccine's efficacy.